Ocular Therapeutix Inc Stock Research

Market Summary

USD3.88-0.01

Market Closed

-0.26%

OCUL Stock Price

OCUL RSI Chart

OCUL Valuation

Market Cap

298.8M

Price/Earnings (Trailing)

-5.03

Price/Sales (Trailing)

6.01

Price/Free Cashflow

-4.98

OCUL Price/Sales (Trailing)

OCUL Profitability

Return on Equity

-128.37%

Return on Assets

-37.42%

Free Cashflow Yield

-20.08%

OCUL Fundamentals

OCUL Revenue

Revenue (TTM)

49.7M

Revenue Y/Y

-1.55%

Revenue Q/Q

-2.45%

OCUL Earnings

Earnings (TTM)

-59.3M

Earnings Y/Y

-1.0K%

Earnings Q/Q

-28.89%

Price Action

52 Week Range

2.576.53

(Low)(High)

Last 7 days

-5.4%

Last 30 days

47.0%

Last 90 days

5.4%

Trailing 12 Months

-25.9%

OCUL Financial Health

Current Ratio

4.98

OCUL Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-1.01

Peers (Alternatives to Ocular Therapeutix)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	442.1B	96.0B	-4.77%	1.21%	23.08	4.6	5.02%	7.14%
LLY	308.1B	29.2B	-6.33%	46.49%	51.07	10.54	5.34%	1.02%
MRK	267.0B	59.0B	-5.13%	34.98%	17.49	4.53	27.84%	112.03%
PFE	245.5B	99.9B	-13.80%	-15.92%	8.25	2.46	45.01%	53.21%
BMY	154.0B	46.7B	0.64%	15.96%	23.07	3.3	2.79%	223.53%
MID-CAP
PRGO	5.0B	4.4B	10.03%	-0.57%	-46.66	1.14	1.80%	57.67%
SUPN	2.2B	659.0M	13.79%	40.18%	57.51	3.29	16.78%	-53.92%
SMALL-CAP
TLRY	1.9B	613.6M	24.42%	-38.51%	-3.79	3.14	37.73%	-7.19%
RETA	1.6B	3.1M	23.90%	79.89%	-5.08	503.44	-77.09%	-12.24%
CGC	1.4B	-	33.79%	-57.23%	-0.46	1.95	-4.11%	-144.36%
ACRS	1.2B	23.5M	12.85%	73.07%	-14.2	49.6	243.57%	-1.04%
CRON	942.1M	112.7M	-	-24.55%	-4.21	8.36	45.53%	40.26%
INVA	885.5M	-	-2.61%	-19.99%	2.65	2.34	10.49%	-16.07%
OCUL	298.8M	49.7M	46.97%	-25.95%	-5.03	6.01	28.95%	32.80%
ENDP	94.1M	2.6B	-43.99%	-88.43%	-0.03	0.04	-13.88%	-4855.92%

Financials for Ocular Therapeutix

Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-0.4%	49,726	49,914	49,366	43,522	38,562
S&GA Expenses	1.6%	38,525	37,915	36,166	35,190	32,864
R&D Expenses	1.9%	52,497	51,497	52,256	50,083	45,129
Interest Expenses	2.1%	6,856	6,717	6,676	6,671	6,718
Net Income	-82.6%	-59,346.00	-32,501.00	-22,216.00	-6,553.00	-88,315.00
Net Income Margin	-83.3%	-1.19*	-0.65*	-0.45*	-0.15*	-
Free Cahsflow	-1.2%	-59,994.00	-59,289.00	-68,103.00	-66,744.00	-

* denotes actual numbers (not divided by Thousands)

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-8.4%	159	173	188	205	218
Current Assets	-9.2%	146	160	175	191	204
Cash Equivalents	-10.1%	121	135	145	164	179
Inventory	3.0%	2	2	1	1	1
Net PPE	7.7%	7	7	7	7	7
Liabilities	4.7%	112	107	108	117	130
Current Liabilities	12.1%	29	26	24	26	25
Shareholder's Equity	-29.7%	46	66	80	88	87
Retained Earnings	-4.2%	-601.30	-577.11	-558.35	-545.80	-541.95
Additional Paid-In Capital	0.7%	648	643	638	634	629
Accumulated Depreciation	-	15	-	-	-	-
Shares Outstanding	0.1%	77	77	77	77	77

* denotes actual numbers (not divided by Millions)

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-0.3%	-57,798.00	-57,611.00	-66,791.00	-65,550.00	-56,643.00
Share Based Compensation	3.0%	16,571	16,089	16,100	14,977	13,240
Cashflow From Investing	-30.9%	-2,196.00	-1,678.00	-1,312.00	-1,194.00	-816.00
Cashflow From Financing	-15.5%	1,663	1,968	4,142	2,851	166,097

Risks for OCUL

What is the probability of a big loss on OCUL?

98.8%

Probability that Ocular Therapeutix stock will be more than 20% underwater in next one year

97.3%

Probability that Ocular Therapeutix stock will be more than 30% underwater in next one year.

72.3%

Probability that Ocular Therapeutix stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does OCUL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ocular Therapeutix was unfortunately bought at previous high price.

Drawdowns

Returns for OCUL

Cumulative Returns on OCUL

-6.3%

7-Year Cumulative Returns

-5.7%

5-Year Cumulative Returns

-4.2%

3-Year Cumulative Returns

What are the long-term rolling returns for OCUL?

FIve years rolling returns for Ocular Therapeutix.

Annualized Returns

Which funds bought or sold OCUL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-01-26	STRS OHIO	unchanged	-	-21,000	44,000	-%
2023-01-25	Hikari Power Ltd	unchanged	-	-23,000	48,000	-%
2023-01-25	DELTEC ASSET MANAGEMENT LLC	reduced	-20.26	-4,436,220	5,206,780	1.49%
2023-01-25	Lindbrook Capital, LLC	sold off	-100	-3,000	-	-%
2023-01-24	Centerpoint Advisors, LLC	unchanged	-	-4,000	10,000	-%
2023-01-19	Quent Capital, LLC	new	-	1,377	1,377	-%
2023-01-18	Verition Fund Management LLC	added	100	43,000	84,000	-%
2023-01-13	BEACON INVESTMENT ADVISORY SERVICES, INC.	unchanged	-	-16,280	33,720	-%
2023-01-09	Founders Capital Management	unchanged	-	-3,000	7,000	-%
2023-01-06	MASSMUTUAL TRUST CO FSB/ADV	added	75.41	-	-	-%

Latest Funds Activity

Are funds buying OCUL calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own OCUL

No. of Funds

Ocular Therapeutix News

Schedule 13G FIlings of Ocular Therapeutix

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 03, 2022	blackrock inc.	6.7%	5,122,835	SC 13G/A
Feb 01, 2022	opaleye management inc.	7.80%	5,974,800	SC 13G/A
Feb 12, 2021	opaleye management inc.	8.65%	9	SC 13G/A
Feb 02, 2021	blackrock inc.	7.3%	5,512,264	SC 13G
Jun 09, 2020	blackrock inc.	4.8%	3,006,167	SC 13G/A
May 21, 2020	summer road llc	17.0%	11,387,656	SC 13D/A
Mar 25, 2020	summer road llc	18.9%	11,024,020	SC 13D/A
Feb 14, 2020	versant side fund iii, l.p.	0.1%	13,007	SC 13G/A
Feb 10, 2020	man group plc	1.58%	760,490	SC 13G/A
Feb 05, 2020	blackrock inc.	5.9%	2,829,644	SC 13G/A

OCUL Fair Value

Recent SEC filings of Ocular Therapeutix

View All Filings

Date Filed	Form Type	Document
Jan 06, 2023	8-K	Current Report
Nov 09, 2022	4	Insider Trading
Nov 07, 2022	8-K	Current Report
Nov 07, 2022	10-Q	Quarterly Report

Latest Insider Trading transactions for OCUL

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-11-07	SUMMER ROAD LLC	bought	25,648	3.5	7,328	-
2022-10-11	SUMMER ROAD LLC	bought	38,993	3.8993	10,000	-
2022-10-10	SUMMER ROAD LLC	bought	39,982	3.9982	10,000	-
2022-09-29	SUMMER ROAD LLC	bought	75,987.7	4.0419	18,800	-
2022-09-28	SUMMER ROAD LLC	bought	4,920	4.1	1,200	-
2022-09-27	SUMMER ROAD LLC	bought	608,322	4.6794	130,000	-
2022-07-01	Ozden Rabia Gurses	acquired	-	-	6,667	chief medical officer
2022-06-16	Warden Charles M	acquired	-	-	8,933	-
2022-06-16	Heier Jeffrey S.	acquired	-	-	8,933	-
2022-06-16	RAINES MERILEE	acquired	-	-	8,933	-

About Ocular Therapeutix

Antony Mattessich

www.ocutx.com

230

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Income Statement

2022-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue, net	$ 11,965	$ 12,153	$ 37,419	$ 31,214
Costs and operating expenses:
Cost, Product and Service [Extensible List]	Product	Product	Product	Product
Cost of product revenue	$ 1,073	$ 1,310	$ 3,528	$ 3,298
Research and development	13,719	12,719	39,919	37,505
Selling and marketing	10,186	9,576	29,390	26,054
General and administrative	8,531	8,077	23,875	24,345
Total costs and operating expenses	33,509	31,682	96,712	91,202
Loss from operations	(21,544)	(19,529)	(59,293)	(59,988)
Other income:
Interest income	285	7	375	27
Interest expense	(1,797)	(1,658)	(5,175)	(4,991)
Change in fair value of derivative liability	(1,133)	23,837	8,598	62,249
Other income (expense), net	1		(1)
Total other income, net	(2,644)	22,186	3,797	57,285
Net (loss) income	$ (24,188)	$ 2,657	$ (55,496)	$ (2,703)
Net (loss) income per share, basic	$ (0.31)	$ 0.03	$ (0.72)	$ (0.04)
Weighted average common shares outstanding, basic	76,975,839	76,552,060	76,829,434	76,317,563
Net (loss) income per share, diluted	$ (0.31)	$ (0.23)	$ (0.73)	$ (0.75)
Weighted average common shares outstanding, diluted	76,975,839	85,446,886	82,598,666	82,086,795
Product
Revenue:
Total revenue, net	$ 11,913	$ 12,153	$ 36,555	$ 31,214
Collaboration revenue
Revenue:
Total revenue, net	$ 52		$ 864

OCUL Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 120,950	$ 164,164
Accounts receivable, net	19,802	21,135
Inventory	1,545	1,250
Prepaid expenses and other current assets	3,318	4,751
Total current assets	145,615	191,300
Property and equipment, net	7,196	6,956
Restricted cash	1,764	1,764
Operating lease assets	4,004	4,867
Total assets	158,579	204,887
Current liabilities:
Accounts payable	5,308	4,592
Accrued expenses and other current liabilities	21,614	20,121
Deferred revenue	603
Operating lease liabilities	1,744	1,624
Total current liabilities	29,269	26,337
Other liabilities:
Operating lease liabilities, net of current portion	4,610	5,924
Derivative liability	11,594	20,192
Deferred revenue, net of current portion	13,533	13,000
Notes payable, net of discount	25,192	25,000
2026 convertible notes, net	28,152	26,435
Total liabilities	112,350	116,888
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at September 30, 2022 and December 31, 2021, respectively
Common stock, $0.0001 par value; 200,000,000 shares authorized and 77,010,385 and 76,731,940 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	8	8
Additional paid-in capital	647,521	633,795
Accumulated deficit	(601,300)	(545,804)
Total stockholders' equity	46,229	87,999
Total liabilities and stockholders' equity	$ 158,579	$ 204,887